People with Parkinson’s disease see movement-related symptoms like walking, balance, and tremor as the most bothersome aspects of their disease, while family members are more concerned about physical impacts like mobility and psychosocial aspects like interpersonal interactions and independence, according to a large-scale international survey. At later stages…
Healthcare services contribute to nearly half the total expenses associated with Parkinson’s disease, but the loss of productivity and the financial burden on patients and their families also have a substantial impact, a study shows. The study estimated the average annual cost per patient with Parkinson’s disease is about…
Note: This story was updated Sept. 16, 2024, to correct that A-dopamine is a form of dopamine. Levodopa, a mainstay in treating Parkinson’s disease, isn’t always well absorbed by the brain or digestive tract, doesn’t last long in the body, and often loses effectiveness with age and disease…
Electroacupuncture reduced cellular hallmarks of Parkinson’s disease, including alpha-synuclein accumulation and nerve cell degeneration, in a mouse model of the disease. That’s according to the findings from a study that also found the treatment, a type of acupuncture where small needles inserted at specific points in the body are…
Ncardia has launched a panel of ready-to-use cell-based assays to simplify the screening and selection of treatment candidates for neurodegenerative diseases, including Parkinson’s disease. The assays are based on human-derived induced pluripotent stem cells (iPSCs), a type of stem cell that can generate nearly all types of cells.
Navamedic is partnering with Alex Therapeutics to offer a new companion app to people with Parkinson’s disease who are treated with Flexilev, the former’s water-soluble minitablet formulation of levodopa and carbidopa. The app, which will be developed by Alex Therapeutics, will provide medication management tools tailored to…
Scientists have discovered how to therapeutically target a class of molecular switches called GTPases that are involved in Parkinson’s disease and other conditions but have long been considered undruggable. The findings of this work, led by researchers at the University of California, San Francisco (UCSF), “create a long-awaited opportunity…
Rune Labs has launched StrivePD-AI, a new feature in its StrivePD app that uses generative artificial intelligence (GenAI) to create monthly clinical reports based on a continuous stream of observations that show how Parkinson’s disease is progressing in the app’s users over time. The company is cleared…
The American Parkinson Disease Association (APDA) has awarded a total of $2.6 million for the 2024-2025 funding year, to support a range of research projects that aim to advance understanding of Parkinson’s disease. The nationwide grassroots network increased its funding package by more than 30% over last year,…
The U.S. Food and Drug Administration (FDA) has cleared Turing Medical’s automated brain mapping technology designed to help doctors develop personalized plans for deep brain stimulation (DBS) and other neuromodulation therapies in people with neurological conditions such as Parkinson’s disease. Called Bullsai Identify, the platform uses artificial intelligence…
Get regular updates to your inbox.
